RenovoRx, Inc. 8-K

What Happened
RenovoRx, Inc. announced on its Form 8-K that it received a Nasdaq deficiency notice on December 31, 2025, stating its common stock failed to meet the $1.00 minimum bid price required under Nasdaq Listing Rule 5550(a)(2). Nasdaq found the stock closed below $1.00 for the 32 consecutive business days prior to the notice. The notice does not have an immediate effect on the listing.

Key Details

• Nasdaq provided an initial 180-calendar-day compliance period under Rule 5810(c)(3)(A), giving RenovoRx until June 30, 2026 to regain compliance.
• To regain compliance the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days prior to June 30, 2026.
• If not regained by June 30, 2026, RenovoRx may be eligible for a second 180-day period if it meets market value and other initial listing standards (except the bid price) and notifies Nasdaq of its intention to cure—potentially by effecting a reverse stock split.
• If the Company does not qualify for or fails to meet requirements during any applicable second period, Nasdaq may move to delist the shares, after which the Company can appeal to a Nasdaq Hearings Panel.

Why It Matters
This notice signals a risk that RenovoRx’s shares could be moved off The Nasdaq Capital Market if the company does not restore its share price above $1.00 for the required period. For investors, the immediate listing is unchanged, but the company has a defined timeline (through June 30, 2026, and possibly an additional 180 days) to fix the issue. Potential future actions—such as a reverse stock split or a delisting appeal—could affect share price, liquidity, and where the stock trades, so investors should monitor the closing bid price and company updates.